## **Core Concept**
Abciximab is a medication used to prevent platelet aggregation during coronary interventions. It works by inhibiting the platelet glycoprotein IIb/IIIa receptor. This receptor plays a crucial role in the final common pathway of platelet aggregation.

## **Why the Correct Answer is Right**
Abciximab is a monoclonal antibody that specifically binds to the glycoprotein IIb/IIIa receptor on the surface of platelets. By blocking this receptor, abciximab prevents fibrinogen from binding to platelets, which is necessary for platelet aggregation to occur. This mechanism effectively inhibits platelet aggregation, reducing the risk of thrombotic complications during procedures like percutaneous coronary intervention (PCI).

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because abciximab does not work by stimulating the glycoprotein IIb/IIIa receptor; rather, it inhibits this receptor.
- **Option B:** This option is incorrect as abciximab's action is not related to the activation of the intrinsic pathway of coagulation.
- **Option C:** This option is incorrect because abciximab does not act by inhibiting the release of ADP from platelets; its action is more direct, targeting the glycoprotein IIb/IIIa receptor.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that abciximab is particularly useful in the setting of acute coronary syndromes and during PCI to prevent thrombotic complications. Its use requires careful monitoring due to the increased risk of bleeding.

## **Correct Answer:** D. Inhibits platelet glycoprotein IIb/IIIa receptor.